StockNews.AI
MIRA
StockNews.AI
11 days

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

1. MIRA's Ketamir-2 shows strong efficacy in diabetic neuropathy animal model. 2. Subjects demonstrated complete symptom reversal, potentially enhancing MIRA's product pipeline.

2 mins saved
Full Article

FAQ

Why Bullish?

The strong efficacy data for Ketamir-2 may attract investor interest, similar to past biotech advancements that boosted stock prices.

How important is it?

The promising results of Ketamir-2 are crucial for MIRA's growth and future funding rounds.

Why Short Term?

Immediate investor reaction expected to favorable data, with longer-term effects contingent on clinical trial success.

Related Companies

KMPHPFEJNJ
Ketamir-2 Demonstrates Strong Efficacy in Diabetic Neuropathy Model, with Some Subjects Achieving Complete Symptom Reversal MIAMI, FLORIDA / ACCESS Newswire / April 16, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), or MIRA, a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic and neuropsychiatric disorders, today announced compelling data demonstrating the efficacy of the oral ketamine analog, Ketamir-2, in a validated animal model of diabetic neuropathy. In the study, Type 2 diabetes was induced in rats using a high-fat diet combined with a low dose of Streptozotocin (STZ).

Related News